These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 10975393

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 24. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
    Ranganathan S, Webber S, Ahuja S, Jaffe R.
    Pediatr Dev Pathol; 2004 Apr; 7(4):348-60. PubMed ID: 14564542
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.
    Rohr JC, Wagner HJ, Lauten M, Wacker HH, Jüttner E, Hanke C, Pohl M, Niemeyer CM.
    Pediatr Transplant; 2008 Jun; 12(4):426-31. PubMed ID: 18466428
    [Abstract] [Full Text] [Related]

  • 27. Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation.
    Kew CE, Lopez-Ben R, Smith JK, Robbin ML, Cook WJ, Gaston RS, Deierhoi MH, Julian BA.
    Transplantation; 2000 Mar 15; 69(5):809-14. PubMed ID: 10755531
    [Abstract] [Full Text] [Related]

  • 28. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R, Shapiro R, Jordan ML, Scantlebury VP, Gritsch HA, Vivas C, Randhawa PS.
    Clin Transplant; 1997 Dec 15; 11(6):574-6. PubMed ID: 9408687
    [Abstract] [Full Text] [Related]

  • 29. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 30. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma.
    Lohrisch CA, Nevill TJ, Barnett MJ, Hogge DE, Connors JM, Keown PA, Gascoyne RD.
    Leuk Lymphoma; 2000 Sep 15; 39(1-2):195-201. PubMed ID: 10975399
    [Abstract] [Full Text] [Related]

  • 31. Thoracic presentations of posttransplant lymphoproliferative disorders.
    Halkos ME, Miller JI, Mann KP, Miller DL, Gal AA.
    Chest; 2004 Dec 15; 126(6):2013-20. PubMed ID: 15596707
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
    Ann Hematol; 2006 Jul 15; 85(7):478-84. PubMed ID: 16586109
    [Abstract] [Full Text] [Related]

  • 34. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
    Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU.
    Transplantation; 2012 Mar 15; 93(5):543-50. PubMed ID: 22234349
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M, Coupes B, Roberts SA, Klapper PE, Byers RJ, Vallely PJ, Ryan K, Picton ML.
    Transplantation; 2013 Feb 15; 95(3):470-8. PubMed ID: 23222821
    [Abstract] [Full Text] [Related]

  • 38. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb 15; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

  • 39. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
    Glez-Chamorro A, Jimenez C, Moreno-Glez E, Glez-Pinto I, Loinaz C, Gomez R, Garcia I, Alonso O, Palma F, Grande C.
    Hepatogastroenterology; 2000 Feb 15; 47(31):211-9. PubMed ID: 10690611
    [Abstract] [Full Text] [Related]

  • 40. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients.
    Köpf S, Tönshoff B.
    Pediatr Nephrol; 2004 Apr 15; 19(4):365-8. PubMed ID: 14963763
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.